January 2024 FDA Recall Tizanidine by Dr. Reddy's Laboratories, Inc.
D-0223-2024 - Presence of Foreign tablets/capsules - identified as tizanidine 2 mg tablets.
This Class II drug recall was voluntarily initiated by Dr. Reddy's Laboratories, Inc. on January 2, 2024 for the product Tizanidine. The FDA reported the reason for recall as presence of foreign tablets/capsules - identified as tizanidine 2 mg tablets.. The product was distributed Nationwide and the recall is currently completed.
Recall Number: D-0223-2024
Presence of Foreign tablets/capsules - identified as tizanidine 2 mg tablets.
01-02-2024
01-17-2024
38,952 bottles
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Completed
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
Dr. Reddy's Laboratories, Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
USA Nationwide
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Tizanidine Tablets, USP 4mg, 150-count bottle, Rx only, Mfd. By: Dr. Reddy's Laboratories Limited, Srikakulam - 532 409 INDIA, NDC 55111-180-15
Batch or Lot Expiration Information
Lot# : T2304007, Exp 7/31/2026
